Antihyperglycemic effect of short-term arginyl-fructose supplementation in subjects with prediabetes and newly diagnosed type 2 diabetes

Randomized, double-blinded, placebo-controlled trial

Su Eun Park, Ok Hwan Kim, Jung Hyun Kwak, Kwang Hyoung Lee, Young In Kwon, Kwang Hoe Chung, Jong Ho Lee

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: A previous study reported that arginyl-fructose may have great value as a functional food with antioxidant and antidiabetic activities. However, there have been few clinical studies on the efficacy of arginyl-fructose supplementation for blood glucose control. Methods: In this double-blind, placebo-controlled study, 60 Korean subjects with prediabetes or type 2 diabetes mellitus were randomly assigned to placebo or test groups. The test group subjects received 1500 mg/day arginyl-fructose. Fasting serum levels of glucose, hemoglobin A1c, insulin, and free fatty acids were measured by 2-hour oral glucose tolerance tests at baseline and after the 6-week intervention. Eleven subjects dropped out or were excluded during the trial. The data for the remaining 49 were statistically analyzed using Student's t-test and paired t-test. Results: After the 6-week intervention, the test group showed significant reductions in serum glucose levels at 30 minutes (-19.4 ± 5.62 mg/dL) and 60 minutes (-15.4 ± 7.01 mg/dL) and reduced glucose area under the curve (-27.4 ± 8.59 mg/dL) compared with those of the placebo control group. The changes (differences from baseline) in serum glucose levels at 60 minutes and glucose area under the curve in the test group differed significantly from those in the control group even after adjusting for baseline values. In contrast, glucose-related biomarkers including hemoglobin A1c, insulin, and C-peptide levels were not significantly improved by the dietary intervention with arginyl-fructose. Conclusions: Arginyl-fructose supplementation (1500 mg/day) may be beneficial for reducing postprandial blood glucose levels in patients with prediabetes or type 2 diabetes mellitus. Trial registration: ClinicalTrials.gov NCT02285231. Registered 11 May 2014.

Original languageEnglish
Article number521
JournalTrials
Volume16
Issue number1
DOIs
Publication statusPublished - 2015 Nov 14

Fingerprint

Prediabetic State
Hypoglycemic Agents
Type 2 Diabetes Mellitus
Placebos
Glucose
Area Under Curve
Blood Glucose
Hemoglobins
Serum
Insulin
Control Groups
Functional Food
C-Peptide
Glucose Tolerance Test
Double-Blind Method
Nonesterified Fatty Acids
fructosyl arginine
Fasting
Antioxidants
Biomarkers

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Pharmacology (medical)

Cite this

@article{3f1d5606abdf4fdebb924b5d4598b243,
title = "Antihyperglycemic effect of short-term arginyl-fructose supplementation in subjects with prediabetes and newly diagnosed type 2 diabetes: Randomized, double-blinded, placebo-controlled trial",
abstract = "Background: A previous study reported that arginyl-fructose may have great value as a functional food with antioxidant and antidiabetic activities. However, there have been few clinical studies on the efficacy of arginyl-fructose supplementation for blood glucose control. Methods: In this double-blind, placebo-controlled study, 60 Korean subjects with prediabetes or type 2 diabetes mellitus were randomly assigned to placebo or test groups. The test group subjects received 1500 mg/day arginyl-fructose. Fasting serum levels of glucose, hemoglobin A1c, insulin, and free fatty acids were measured by 2-hour oral glucose tolerance tests at baseline and after the 6-week intervention. Eleven subjects dropped out or were excluded during the trial. The data for the remaining 49 were statistically analyzed using Student's t-test and paired t-test. Results: After the 6-week intervention, the test group showed significant reductions in serum glucose levels at 30 minutes (-19.4 ± 5.62 mg/dL) and 60 minutes (-15.4 ± 7.01 mg/dL) and reduced glucose area under the curve (-27.4 ± 8.59 mg/dL) compared with those of the placebo control group. The changes (differences from baseline) in serum glucose levels at 60 minutes and glucose area under the curve in the test group differed significantly from those in the control group even after adjusting for baseline values. In contrast, glucose-related biomarkers including hemoglobin A1c, insulin, and C-peptide levels were not significantly improved by the dietary intervention with arginyl-fructose. Conclusions: Arginyl-fructose supplementation (1500 mg/day) may be beneficial for reducing postprandial blood glucose levels in patients with prediabetes or type 2 diabetes mellitus. Trial registration: ClinicalTrials.gov NCT02285231. Registered 11 May 2014.",
author = "Park, {Su Eun} and Kim, {Ok Hwan} and Kwak, {Jung Hyun} and Lee, {Kwang Hyoung} and Kwon, {Young In} and Chung, {Kwang Hoe} and Lee, {Jong Ho}",
year = "2015",
month = "11",
day = "14",
doi = "10.1186/s13063-015-1036-z",
language = "English",
volume = "16",
journal = "Trials",
issn = "1745-6215",
publisher = "BioMed Central",
number = "1",

}

Antihyperglycemic effect of short-term arginyl-fructose supplementation in subjects with prediabetes and newly diagnosed type 2 diabetes : Randomized, double-blinded, placebo-controlled trial. / Park, Su Eun; Kim, Ok Hwan; Kwak, Jung Hyun; Lee, Kwang Hyoung; Kwon, Young In; Chung, Kwang Hoe; Lee, Jong Ho.

In: Trials, Vol. 16, No. 1, 521, 14.11.2015.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Antihyperglycemic effect of short-term arginyl-fructose supplementation in subjects with prediabetes and newly diagnosed type 2 diabetes

T2 - Randomized, double-blinded, placebo-controlled trial

AU - Park, Su Eun

AU - Kim, Ok Hwan

AU - Kwak, Jung Hyun

AU - Lee, Kwang Hyoung

AU - Kwon, Young In

AU - Chung, Kwang Hoe

AU - Lee, Jong Ho

PY - 2015/11/14

Y1 - 2015/11/14

N2 - Background: A previous study reported that arginyl-fructose may have great value as a functional food with antioxidant and antidiabetic activities. However, there have been few clinical studies on the efficacy of arginyl-fructose supplementation for blood glucose control. Methods: In this double-blind, placebo-controlled study, 60 Korean subjects with prediabetes or type 2 diabetes mellitus were randomly assigned to placebo or test groups. The test group subjects received 1500 mg/day arginyl-fructose. Fasting serum levels of glucose, hemoglobin A1c, insulin, and free fatty acids were measured by 2-hour oral glucose tolerance tests at baseline and after the 6-week intervention. Eleven subjects dropped out or were excluded during the trial. The data for the remaining 49 were statistically analyzed using Student's t-test and paired t-test. Results: After the 6-week intervention, the test group showed significant reductions in serum glucose levels at 30 minutes (-19.4 ± 5.62 mg/dL) and 60 minutes (-15.4 ± 7.01 mg/dL) and reduced glucose area under the curve (-27.4 ± 8.59 mg/dL) compared with those of the placebo control group. The changes (differences from baseline) in serum glucose levels at 60 minutes and glucose area under the curve in the test group differed significantly from those in the control group even after adjusting for baseline values. In contrast, glucose-related biomarkers including hemoglobin A1c, insulin, and C-peptide levels were not significantly improved by the dietary intervention with arginyl-fructose. Conclusions: Arginyl-fructose supplementation (1500 mg/day) may be beneficial for reducing postprandial blood glucose levels in patients with prediabetes or type 2 diabetes mellitus. Trial registration: ClinicalTrials.gov NCT02285231. Registered 11 May 2014.

AB - Background: A previous study reported that arginyl-fructose may have great value as a functional food with antioxidant and antidiabetic activities. However, there have been few clinical studies on the efficacy of arginyl-fructose supplementation for blood glucose control. Methods: In this double-blind, placebo-controlled study, 60 Korean subjects with prediabetes or type 2 diabetes mellitus were randomly assigned to placebo or test groups. The test group subjects received 1500 mg/day arginyl-fructose. Fasting serum levels of glucose, hemoglobin A1c, insulin, and free fatty acids were measured by 2-hour oral glucose tolerance tests at baseline and after the 6-week intervention. Eleven subjects dropped out or were excluded during the trial. The data for the remaining 49 were statistically analyzed using Student's t-test and paired t-test. Results: After the 6-week intervention, the test group showed significant reductions in serum glucose levels at 30 minutes (-19.4 ± 5.62 mg/dL) and 60 minutes (-15.4 ± 7.01 mg/dL) and reduced glucose area under the curve (-27.4 ± 8.59 mg/dL) compared with those of the placebo control group. The changes (differences from baseline) in serum glucose levels at 60 minutes and glucose area under the curve in the test group differed significantly from those in the control group even after adjusting for baseline values. In contrast, glucose-related biomarkers including hemoglobin A1c, insulin, and C-peptide levels were not significantly improved by the dietary intervention with arginyl-fructose. Conclusions: Arginyl-fructose supplementation (1500 mg/day) may be beneficial for reducing postprandial blood glucose levels in patients with prediabetes or type 2 diabetes mellitus. Trial registration: ClinicalTrials.gov NCT02285231. Registered 11 May 2014.

UR - http://www.scopus.com/inward/record.url?scp=84946935571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946935571&partnerID=8YFLogxK

U2 - 10.1186/s13063-015-1036-z

DO - 10.1186/s13063-015-1036-z

M3 - Article

VL - 16

JO - Trials

JF - Trials

SN - 1745-6215

IS - 1

M1 - 521

ER -